At the news
? BULLISHIMPACT 5/10 PRESS-RELEASE filed Nov 4, 2026 at 08:00 ET
Rhythm Pharmaceuticals announced that NICE issued positive guidance expanding IMCIVREE (setmelanotide) reimbursement to adults with Bardet-Biedl syndrome in England, Wales and Northern Ireland, building on prior pediatric coverage. This regulatory win expands the addressable patient population for IMCIVREE in the UK, supporting the company's commercial momentum in rare obesity indications.
- NICE issued positive guidance for IMCIVREE (setmelanotide) to include adults with genetically confirmed Bardet-Biedl syndrome (BBS)
- Expanded reimbursement allows adults to access funded treatment through the NHS in England, Wales and Northern Ireland
- Prior NICE recommendation (May 2024) covered patients ages 6 to 17 years
- Company market cap is $6.4B with strong institutional support
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access